Richard Friedman to Anticoagulants
This is a "connection" page, showing publications Richard Friedman has written about Anticoagulants.
Connection Strength
2.927
-
Clinical experience with novel oral anticoagulants for thromboprophylaxis after elective hip and knee arthroplasty. Arterioscler Thromb Vasc Biol. 2015 Apr; 35(4):771-8.
Score: 0.414
-
Novel oral anticoagulants for VTE prevention in orthopedic surgery: overview of phase 3 trials. Orthopedics. 2011 Oct; 34(10):795-804.
Score: 0.326
-
New oral anticoagulants for venous thromboembolism prophylaxis in orthopaedic surgery. Instr Course Lect. 2011; 60:291-300.
Score: 0.309
-
New oral anticoagulants for thromboprophylaxis after total hip or knee arthroplasty. Orthopedics. 2009 Dec; 32(12 Suppl):79-84.
Score: 0.287
-
Dabigatran etexilate: pivotal trials for venous thromboembolism prophylaxis after hip or knee arthroplasty. Clin Appl Thromb Hemost. 2009 Sep-Oct; 15 Suppl 1:25S-31S.
Score: 0.280
-
Optimal duration of prophylaxis for venous thromboembolism following total hip arthroplasty and total knee arthroplasty. J Am Acad Orthop Surg. 2007 Mar; 15(3):148-55.
Score: 0.237
-
Cost analyses of extended prophylaxis with enoxaparin after hip arthroplasty. Clin Orthop Relat Res. 2000 Jan; (370):171-82.
Score: 0.144
-
The role of low molecular weight heparin in total knee arthroplasty. Am J Knee Surg. 1999; 12(1):55-60.
Score: 0.135
-
Benefit-risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplasty. Vasc Health Risk Manag. 2014; 10:157-67.
Score: 0.097
-
Concomitant use of medication with antiplatelet effects in patients receiving either rivaroxaban or enoxaparin after total hip or knee arthroplasty. Thromb Res. 2012 Aug; 130(2):147-51.
Score: 0.083
-
Economic impact of venous thromboembolism after hip and knee arthroplasty: potential impact of rivaroxaban. Expert Rev Pharmacoecon Outcomes Res. 2011 Jun; 11(3):299-306.
Score: 0.080
-
Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial. Thromb Haemost. 2011 Apr; 105(4):721-9.
Score: 0.078
-
Practice patterns in the use of venous thromboembolism prophylaxis after total joint arthroplasty--insights from the Multinational Global Orthopaedic Registry (GLORY). Am J Orthop (Belle Mead NJ). 2010 Sep; 39(9 Suppl):14-21.
Score: 0.076
-
Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008 Jun 26; 358(26):2765-75.
Score: 0.065
-
Potent anticoagulants are associated with a higher all-cause mortality rate after hip and knee arthroplasty. Clin Orthop Relat Res. 2008 Aug; 466(8):2009-11; author reply 2012-4.
Score: 0.065
-
Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty. 2009 Jan; 24(1):1-9.
Score: 0.064
-
Insufficient duration of venous thromboembolism prophylaxis after total hip or knee replacement when compared with the time course of thromboembolic events: findings from the Global Orthopaedic Registry. J Bone Joint Surg Br. 2007 Jun; 89(6):799-807.
Score: 0.060
-
Comment: low-dose warfarin for prevention of symptomatic thromboembolism after orthopedic surgery. Ann Pharmacother. 2005 Nov; 39(11):1954-5; author reply 1955.
Score: 0.054
-
Treatment of venous thromboembolism: adherence to guidelines and impact of physician knowledge, attitudes, and beliefs. J Vasc Surg. 2005 Oct; 42(4):726-33.
Score: 0.054
-
Prevention of venous thromboembolism after hip or knee arthroplasty: findings from a 2008 survey of US orthopedic surgeons. J Arthroplasty. 2012 May; 27(5):659-66.e5.
Score: 0.020